Clinical Trial

GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C mutation.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-24; most recent amendment 2024-07-03.
Trial Details
NCT Number NCT06435455
Lead Sponsor Suzhou Genhouse Bio Co., Ltd.
Collaborators: Zhejiang Cancer Hospital
Conditions Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
Enrollment 126 participants
Start Date 2024-07-01
Primary Completion 2027-09-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-08